We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck's Ebola Vaccine Gets Conditional Approval in Europe
Read MoreHide Full Article
Merck & Co., Inc. (MRK - Free Report) announced that the European Commission has granted conditional marketing approval to its investigational vaccine for Ebola Zaire disease, V920. The vaccine, which has been approved for active immunization of individuals 18 years of age or older, will be marketed by the trade name of Ervebo.
With the approval, Merck can initiate manufacturing of licensed doses in Germany. These doses are expected to be available in the third quarter of 2020
Merck’s shares have risen 9% this year so far compared with the industry’s increase of 3.6%.
The European Commission’s conditional approval was expected as last month, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) gave a positive opinion, recommending conditional marketing approval of Ervebo. Ervebo is under priority review in the United States with a FDA decision expected on Mar 14 next year.
Some other companies like Inovio Pharmaceuticals’ (INO - Free Report) and Regeneron (REGN - Free Report) are also currently evaluating Ebola vaccine candidates. Regeneron has four investigational therapies for Ebola virus infection in its pipeline. In August, Glaxo (GSK - Free Report) granted exclusive technology license of its Ebola vaccine candidates to Sabin Vaccine Institute, which now takes care of development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and Marburg virus.
Vaccine is an important therapeutic area for Merck. The company has several marketed vaccines in its portfolio like Gardasil/Gardasil 9, ProQuad/M-M-R II/Varivax, RotaTeq, Pneumovax 23 and Zostavax. Among these, human papillomavirus vaccine, Gardasil/Gardasil 9 is a key top-line driver of the company, recording sales of more than $3 billion in the first nine months of 2019.
Apart from the Ebola vaccine candidate, Merck is studying an investigational 15-valent pneumococcal conjugate vaccine candidate, V114, in late-stage studies. The candidate is being developed as a preventive treatment for invasive pneumococcal disease in pediatric as well as adult patients.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Merck's Ebola Vaccine Gets Conditional Approval in Europe
Merck & Co., Inc. (MRK - Free Report) announced that the European Commission has granted conditional marketing approval to its investigational vaccine for Ebola Zaire disease, V920. The vaccine, which has been approved for active immunization of individuals 18 years of age or older, will be marketed by the trade name of Ervebo.
With the approval, Merck can initiate manufacturing of licensed doses in Germany. These doses are expected to be available in the third quarter of 2020
Merck’s shares have risen 9% this year so far compared with the industry’s increase of 3.6%.
The European Commission’s conditional approval was expected as last month, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) gave a positive opinion, recommending conditional marketing approval of Ervebo. Ervebo is under priority review in the United States with a FDA decision expected on Mar 14 next year.
Some other companies like Inovio Pharmaceuticals’ (INO - Free Report) and Regeneron (REGN - Free Report) are also currently evaluating Ebola vaccine candidates. Regeneron has four investigational therapies for Ebola virus infection in its pipeline. In August, Glaxo (GSK - Free Report) granted exclusive technology license of its Ebola vaccine candidates to Sabin Vaccine Institute, which now takes care of development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and Marburg virus.
Vaccine is an important therapeutic area for Merck. The company has several marketed vaccines in its portfolio like Gardasil/Gardasil 9, ProQuad/M-M-R II/Varivax, RotaTeq, Pneumovax 23 and Zostavax. Among these, human papillomavirus vaccine, Gardasil/Gardasil 9 is a key top-line driver of the company, recording sales of more than $3 billion in the first nine months of 2019.
Apart from the Ebola vaccine candidate, Merck is studying an investigational 15-valent pneumococcal conjugate vaccine candidate, V114, in late-stage studies. The candidate is being developed as a preventive treatment for invasive pneumococcal disease in pediatric as well as adult patients.
Merck currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>